BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, March 21, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Nov. 13, 2014
View Archived Issues
R-Tech Ueno completes phase I/II study of RU-101 for severe dry eye
Read More
ArQule collaborates with NIH on development of ARQ-092 in Proteus syndrome
Read More
VaxInnate reports topline results from phase I study of quadrivalent influenza vaccine candidate
Read More
Daiichi Sankyo selects research collaborations for 2014 TaNeDS drug discovery initiative
Read More
Novel anti-PD-L1 therapy shows promise in in vitro and in vivo bladder tumor models
Read More
OncoEthix updates on OTX-015 clinical trial program
Read More
Intarcia and Servier partner on ITCA-650 outside U.S. and Japan
Read More
Alios BioPharma presents preclinical data for novel nucleoside HCV polymerase inhibitors
Read More
ScinoPharm and Nanjing King-friend collaborate on Chinese development of regadenoson
Read More
GC-021109 receives FDA fast track designation
Read More
The Duchenne Alliance provides funds for follistatin gene therapy trial
Read More
Novel GPR119 agonists disclosed by Yuhan Corp.
Read More
AbbVie prepares new anti-RSV thiazoles
Read More
Matinas BioPharma begins dosing in first-in-human trial of MAT-9001
Read More
Phase III results presented for liraglutide as weight management drug in adults with obesity
Read More
HEP-114 dose-dependently improves liver function in patients with toxic-induced liver injury
Read More
E.U. orphan drug designation given to Xeris' soluble glucagon
Read More
NNZ-2566 shows clinical benefit phase II Rett syndrome trial
Read More
GlaxoSmithKline submits variation to the MAA for Revolade
Read More
Boehringer Ingelheim decides not to exercise option for Athera cardiovascular antibody
Read More
Highland Therapeutics reports topline data from phase III trial of HLD-200
Read More
Phase II SBIR grant supports ONL Therapeutics' development of ONL-101 in retinal detachment
Read More
Isis and AstraZeneca to collaborate on targeted delivery of antisense oligonucleotides
Read More
